Low blood levels of LRG1 before radical prostatectomy identify patients with high risk of progression to castration-resistant prostate cancer by Guldvik, IJ, Braadland, PR, Sivanesan, S, Ramberg, H, Kristensen, G, Tennstedt, P, Røder, A, Schlomm, T, Berge, V, Eri, LM, Lilleby, W, Mills, IG, Taskén, KA

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial by Oza, A, Cook, A, Pfisterer, J, Embleton, A, Ledermann, J, Pujade-Lauraine, E, Kristensen, G, Carey, M, Beale, P, Cervantes, A, Park-Simon, T, Rustin, G, Joly, F, Mirza, M, Plante, M, Quinn, M, Poveda, A, Jayson, G, Stark, D, Swart, A, Farrelly, L, Kaplan, R, Parmar, M, Perren, T